Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации11449Conference ProceedingsPharmacoepidemiological aspects of the therapy of recurrent urinary tract infections in children with vesicoureteral refluxShevtsovaOlga Sergeevna<p>Assistant of the Department of Pediatrics and Neonatology at the Institute of Continuing Medical and Pharmaceutical Education</p>skorayaolya@gmail.comhttps://orcid.org/0000-0003-3490-7623ShishimorovIvan Nikolaevich<p>MD, Associate Professor, Head of the Department of Pediatrics and Neonatology, Institute of Continuing<br />Medical and Pharmaceutical Education</p>drshishimorov@gmail.comhttps://orcid.org/0000-0001-6098-7028ShaposhnikovaNatalya Fedorovna<p>Associate Professor of the Department of Pediatrics and Neonatology Institute of Continuing Medical and Pharmaceutical Education</p>nataliashaposhnikova1957@gmail.comhttps://orcid.org/0000-0001-7007-365XVolgograd State Medical University0110202615S12162170603202605042026Copyright © 2026, Shevtsova O.S., Shishimorov I.N., Shaposhnikova N.F.2026<p style="text-align: justify;">A retrospective study included 45 children with vesicoureteral reflux (VUR) and recurrent urinary tract infections (UTIs) hospitalized in 2021 (mean age 71.4 years, 93.3% girls). Grade 2 VUR predominated (86.7%). Bacteriuria was confirmed in only 15.6% of cases. Furagin was the most frequently prescribed agent (20.0%), followed by co-trimoxazole (8.9%) and nitroxoline (6.7%). No statistically significant association was found between the choice of co-trimoxazole and confirmed bacteriuria (p=0.11), indicating an empirical approach. Analysis of compliance with the 2021 clinical guidelines revealed that in half of the cases, therapy was not fully rational: data on uropathogen resistance were insufficiently considered, and the rationale for long-term prophylaxis was lacking. These findings necessitate a revision of pharmacotherapy approaches towards strict consideration of microbial sensitivity, in accordance with the updated 2024 guidelines.</p>pharmacoepidemiologychildrenurinary tract infectionsvesicoureteral refluxurosepticsclinical guidelinesantibiotic resistanceфармакоэпидемиологиядетиинфекции мочевыводящих путейпузырно-мочеточниковый рефлюксуросептикиклинические рекомендацииантибиотикорезистентность1.Sohail AM, Satapathy AK, Agrawal K, et al. Impact of urinary tract infection on progression of renal scars and formation of new scars in patients with primary vesicoureteric reflux. Afr J Paediatr Surg. 2024 Aug 23. doi:10.4103/ajps.ajps_18_242.Hains DS, Starr MC, Schwaderer AL. Glomerular filtration rate changes following UTI in children with vesicoureteral reflux. JAMA Pediatr. 2024 Oct 24. doi:10.1001/jamapediatrics.2024.42103.Baltesová T, Podracká Ľ, Sádová E, et al. Long-term observation of functional structural changes in children with vesicoureteric reflux. CzMA J Exp Pediatr. 2023;15(2):45-52.4.National Institute for Health and Care Excellence (NICE). Urinary tract infection in under 16s: diagnosis and management. NICE guideline NG224. Published July 27, 2022. Accessed March 6, 2026. https://www.nice.org.uk/guidance/ng2245.Инфекция мочевых путей : клинические рекомендации / М-во здравоохранения Рос. Федерации, Союз педиатров России [и др.]. – Москва, 2024. – 115 с. – URL: https://cr.minzdrav.gov.ru/recomend/28 (дата обращения: 25.02.2026). – Текст : электронный.